Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy? - Wikidata - awgldk - TriplyDB

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?

http://www.wikidata.org/entity/Q34810730

about

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?

http://www.wikidata.org/entity/Q34810730

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Is neoadjuvant androgen depriv ...... with definitive radiotherapy?

@ast

Is neoadjuvant androgen depriv ...... with definitive radiotherapy?

@en

Is neoadjuvant androgen depriv ...... with definitive radiotherapy?

@nl

type

label

Is neoadjuvant androgen depriv ...... with definitive radiotherapy?

@ast

Is neoadjuvant androgen depriv ...... with definitive radiotherapy?

@en

Is neoadjuvant androgen depriv ...... with definitive radiotherapy?

@nl

prefLabel

Is neoadjuvant androgen depriv ...... with definitive radiotherapy?

@ast

Is neoadjuvant androgen depriv ...... with definitive radiotherapy?

@en

Is neoadjuvant androgen depriv ...... with definitive radiotherapy?

@nl

P1433

Q34810730-F3004E5C-B6BE-4AD5-8B5D-034D586E36BD

P1476

Q34810730-65677D0E-7A97-442E-9BA7-91495DDE3468

P2093

Q34810730-1230C071-55ED-4ECA-A0B1-7116098F2633

Q34810730-8F5D4E12-A8C0-4823-BB70-5838C49112F8

Q34810730-B8C3388D-891B-4751-A8D5-9BB110148107

Q34810730-CDE1F265-13C8-4A26-BC88-16178DF71C4B

Q34810730-E8FBF342-7147-46F2-B783-7D0D6B60CAA6

P2860

Q34810730-0132F0F7-2612-49CD-A770-8CC8A4F3E049

Q34810730-01F1FFCA-4C37-48C4-841E-197C5DCBF457

Q34810730-04A4FFEF-3BA6-4F18-A17E-D2D2BD95FAB6

Q34810730-15FB0DF7-D3D0-4A40-8659-DFD3EBA05A45

Q34810730-23DEB29F-DBDB-49BC-BCD9-A1BB59E76364

Q34810730-303051F3-591B-4C32-95ED-7C94499CDD98

Q34810730-663FCEF8-288C-460F-95E8-399C27E194E8

Q34810730-66B56AC3-ACF7-429E-8E64-C0F33502902F

Q34810730-89D74782-ABAA-42DD-9B28-5D1C24ADA3E2

Q34810730-8C26F299-FFC5-4708-AEF2-376CDE28F39E

P304

Q34810730-414F793D-B84B-4AB3-A0B0-1F4C01BA3787

P31

Q34810730-1E61107A-E954-4113-A4EF-D5FA9C7D8484

P356

Q34810730-29580616-42C3-4F4E-BE63-82B6068AA95B

P433

Q34810730-D5F87E9B-8B2B-4EBE-A314-A0380BA2B20C

P478

Q34810730-68D18268-DD28-4849-908B-4CB4D1BB2CCC

P577

Q34810730-7EFDAFB5-A1DC-4D34-AEA3-0851F646061B

P5875

Q34810730-B185FA03-4E09-48C8-B607-C60037F903E5

P698

Q34810730-8F847C1A-B8EF-4D6C-AA51-C52CF84DF9DA

P932

Q34810730-893FA26A-3308-42AC-827F-8586C756B5C2

P356

ROJ.2014.32.4.247

P1433

Radiation oncology journal

P1476

Is neoadjuvant androgen depriv ...... with definitive radiotherapy?

@en

P2093

Cheol Kwak

http://www.w3.org/2001/XMLSchema#string

Eunsik Lee

http://www.w3.org/2001/XMLSchema#string

Keun-Yong Eom

http://www.w3.org/2001/XMLSchema#string

Sang Eun Lee

http://www.w3.org/2001/XMLSchema#string

Sung W Ha

http://www.w3.org/2001/XMLSchema#string

P2860

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.

Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials.

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

National practice patterns and time trends in androgen ablation for localized prostate cancer.

Controversies in prostate cancer radiotherapy: consensus development.

NCCN clinical practice guidelines in oncology: prostate cancer.

EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials.

P304

247-255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3857/ROJ.2014.32.4.247

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270659566

http://www.w3.org/2001/XMLSchema#string

P698

25568853

http://www.w3.org/2001/XMLSchema#string

P932

4282999

http://www.w3.org/2001/XMLSchema#string